171 related articles for article (PubMed ID: 28723497)
1. Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma.
de Velasco G; Gray KP; Hamieh L; Urun Y; Carol HA; Fay AP; Signoretti S; Kwiatkowski DJ; McDermott DF; Freedman M; Pomerantz MM; Choueiri TK
Eur Urol Focus; 2016 Dec; 2(6):633-639. PubMed ID: 28723497
[TBL] [Abstract][Full Text] [Related]
2. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for metastatic renal cell carcinoma.
Unverzagt S; Moldenhauer I; Nothacker M; Roßmeißl D; Hadjinicolaou AV; Peinemann F; Greco F; Seliger B
Cochrane Database Syst Rev; 2017 May; 5(5):CD011673. PubMed ID: 28504837
[TBL] [Abstract][Full Text] [Related]
4. Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib.
Numakura K; Tsuchiya N; Kagaya H; Takahashi M; Tsuruta H; Inoue T; Narita S; Huang M; Satoh S; Niioka T; Miura M; Habuchi T
Anticancer Drugs; 2017 Jan; 28(1):97-103. PubMed ID: 27564227
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma.
Diekstra MH; Belaustegui A; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; García-Donas J; Rodríguez-Antona C; Rini BI; Guchelaar HJ
Pharmacogenomics J; 2017 Jan; 17(1):42-46. PubMed ID: 26810136
[TBL] [Abstract][Full Text] [Related]
6. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
Beuselinck B; Lambrechts D; Van Brussel T; Wolter P; Cardinaels N; Joniau S; Lerut E; Karadimou A; Couchy G; Sebe P; Ravaud A; Zerbib M; Caty A; Paridaens R; Schöffski P; Verkarre V; Berger J; Patard JJ; Zucman-Rossi J; Oudard S
Acta Oncol; 2014 Oct; 53(10):1413-22. PubMed ID: 24874929
[TBL] [Abstract][Full Text] [Related]
7. Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.
Diekstra MH; Liu X; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Eur J Clin Pharmacol; 2015 Dec; 71(12):1477-84. PubMed ID: 26387812
[TBL] [Abstract][Full Text] [Related]
8. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
[TBL] [Abstract][Full Text] [Related]
9. Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer.
Mbatchi LC; Gassiot M; Pourquier P; Goberna A; Mahammedi H; Mourey L; Joly F; Lumbroso S; Evrard A; Houede N
Cancer Chemother Pharmacol; 2017 Sep; 80(3):653-659. PubMed ID: 28676933
[TBL] [Abstract][Full Text] [Related]
10. Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.
Chu YH; Li H; Tan HS; Koh V; Lai J; Phyo WM; Choudhury Y; Kanesvaran R; Chau NM; Toh CK; Ng QS; Tan PH; Chowbay B; Tan MH
PLoS One; 2015; 10(8):e0134102. PubMed ID: 26244574
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.
Dornbusch J; Walter M; Gottschalk A; Obaje A; Junker K; Ohlmann CH; Meinhardt M; Zacharis A; Zastrow S; Schoffer O; Grimm MO; Klug SJ; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1171-82. PubMed ID: 26935927
[TBL] [Abstract][Full Text] [Related]
12. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; van Poppel H; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; Joly F; Lebret T; Gravis G; Deplanque G; Descazeaud A; Leclercq NR; Molinié V; Patard JJ; Teghom C; Elaidi R; Zucman-Rossi J; Oudard S
Acta Oncol; 2014 Jan; 53(1):103-12. PubMed ID: 23421954
[TBL] [Abstract][Full Text] [Related]
13. Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?
Bersanelli M; Iacovelli R; Buti S; Houede N; Laguerre B; Procopio G; Lheureux S; Fischer R; Negrier S; Ravaud A; Oudard S; Escudier B; Albiges L; Porta C
Eur Urol Oncol; 2021 Apr; 4(2):274-281. PubMed ID: 31331862
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy for metastatic renal cell carcinoma.
Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
[TBL] [Abstract][Full Text] [Related]
15. Association analysis of SNPs present in plasma with adverse events and population pharmacokinetics in Chinese sunitinib treated patients with renal cell carcinoma.
Zhang Y; Mai H; Guo G; Bi G; Hao G; Li Y; Wang X; Cheng L; Wang J; Dong R; Liu Z; Chen L; Qu H
Oncotarget; 2018 Mar; 9(18):14109-14123. PubMed ID: 29581831
[TBL] [Abstract][Full Text] [Related]
16. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
[TBL] [Abstract][Full Text] [Related]
17. A Genetic Polymorphism in
Liu X; Swen JJ; Diekstra MHM; Boven E; Castellano D; Gelderblom H; Mathijssen RHJ; Vermeulen SH; Oosterwijk E; Junker K; Roessler M; Alexiusdottir K; Sverrisdottir A; Radu MT; Ambert V; Eisen T; Warren A; Rodríguez-Antona C; García-Donas J; Böhringer S; Koudijs KKM; Kiemeney LALM; Rini BI; Guchelaar HJ
Clin Cancer Res; 2018 May; 24(10):2350-2356. PubMed ID: 29490989
[No Abstract] [Full Text] [Related]
18. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib.
Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; de la Taille A; Tourani JM; Bigot P; Linassier C; Négrier S; Berger J; Patard JJ; Zucman-Rossi J; Oudard S
Br J Cancer; 2013 Mar; 108(4):887-900. PubMed ID: 23462807
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
Kim HR; Park HS; Kwon WS; Lee JH; Tanigawara Y; Lim SM; Kim HS; Shin SJ; Ahn JB; Rha SY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):825-35. PubMed ID: 24013576
[TBL] [Abstract][Full Text] [Related]
20. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy.
Wang P; Yin T; Ma HY; Liu DQ; Sheng YH; Wang C; Zhou BT
Epilepsy Res; 2015 Nov; 117():52-7. PubMed ID: 26421491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
